Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Astellas contributes to Mitokyne's $45mm Series A

Executive Summary

Mitokyne Inc. (developing drugs that improve mitochondrial function) raised $45mm in Series A funding from Astellas Pharma Inc., MPM Capital, and Longwood Founders Fund, which each add a board member. Concurrent with the financing, the company and Astellas penned a deal in which Mitokyne agreed to lead the research and discovery activities, while Astellas handles all clinical development and commercialization. The drug candidates will be aimed at mitochondria-related diseases such as genetic, metabolic, and neurodegenerative conditions and aging. In addition to getting a license to any drugs, Astellas also has the exclusive right to acquire Mitokyne outright during certain periods of their five-year alliance. Money for the acquisition alone could reach $500mm, which includes Astellas’ investment in the Series A.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies